Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Nov;69(11):6702-6.
doi: 10.1128/IAI.69.11.6702-6706.2001.

Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection

Affiliations

Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection

J S Brown et al. Infect Immun. 2001 Nov.

Erratum in

  • Infect Immun. 2004 Nov;72(11):6755

Abstract

There has been considerable recent research into protein based Streptococcus pneumoniae vaccines as alternatives to the existing capsular antigen vaccines. PiuA and PiaA (formerly Pit1A and Pit2A) are recently identified lipoprotein components of S. pneumoniae iron uptake ABC transporters which are required for full virulence and are likely to be expressed on the surface of the bacterial cell membrane. We investigated the efficacy of recombinant PiuA and PiaA proteins at eliciting protective immunity in mice against systemic infection with S. pneumoniae. Both recombinant PiuA and PiaA generated antibody responses that cross-reacted with each other but not with pneumolysin and reacted with identical proteins from nine different S. pneumoniae serotypes. Mice immunized with recombinant PiuA and PiaA were protected against systemic challenge to a degree similar to those immunized with an existing protein vaccine candidate, PdB (a genetically modified pneumolysin toxoid). Immunization with a combination of both PiuA and PiaA resulted in additive protection and was highly protective against systemic infection with S. pneumoniae. PiuA and PiaA are therefore promising additional candidates for a novel S. pneumoniae vaccine using protein antigens.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
(A) Coomassie blue-stained SDS-PAGE gel of purified His6-PiuA and His6-PiaA proteins showing their relative masses and purity. (B) Western blot of purified His6-PiuA and His6-PiaA proteins probed with monoclonal anti-His6 tag antibody (1 in 3,000 dilution).
FIG. 2
FIG. 2
Western blots of purified His6-PiuA, His6-PiaA, and PdB proteins (A) and S. pneumoniae whole-cell lysates (B) probed with anti-alum, anti-PiuA, anti-PiaA, antiPiuA-PiaA, or anti-PdB sera (1 in 3,000 dilution). The relative molecular mass is indicated on the left.
FIG. 3
FIG. 3
Survival curves for groups of 12 to 15 mice vaccinated with His6-PiuA (triangles), His6-PiaA (circles), PdB (diamonds), His6-PiuA combined with His6-PiaA (open squares) or alum-PBS alone (filled squares) after IP challenge with 106 CFU of S. pneumoniae. Symbols: ▪, alum; ▵, PiuA; ⋄, PdB; ○, PiaA; □, PiuA + PiaA.

Similar articles

Cited by

References

    1. Alexander J E, Lock R A, Peeters C C A M, Poolman J T, Andrew P W, Mitchell T J, Hansman D, Paton J C. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun. 1994;62:5683–5688. - PMC - PubMed
    1. Alonso De Velasco E, Verheul A F M, Snippe H. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev. 1995;59:591–603. - PMC - PubMed
    1. Avery O T, MacLeod C M, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med. 1944;79:137–158. - PMC - PubMed
    1. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen J R, Elvin L, Ensor K M, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K. Efficacy, safety, and immunogenicity of heptavalent pneumococcal vaccine in children. Pediatr Infect Dis J. 2000;19:187–195. - PubMed
    1. Briles D E, Tart R C, Wu H Y, Ralph B A, Russell M W, McDaniel L S. Systemic and mucosal protective immunity to pneumococcal surface protein A. Ann N Y Acad Sci. 1998;797:118–126. - PubMed

Publication types

MeSH terms